<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2025-1-74-83</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-2581</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Новая комплексная клиническая классификация степени тяжести синдрома сухого глаза 2024. Часть 2. Алгоритм лечения — мнение экспертов-офтальмологов</article-title><trans-title-group xml:lang="en"><trans-title>New Comprehensive Clinical Classification of the Dry Eye Syndrome Severity 2024. Part 2. Treatment Algorithm — the Opinion of Ophthalmologists</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-5112-5321</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трубилин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Trubilin</surname><given-names>А. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трубилин Александр Владимирович, кандидат медицинских наук, доцент кафедры офтальмологии</p><p>Волоколамское шоссе, 91, Москва, 125371</p></bio><bio xml:lang="en"><p>Trubilin Alexander. V., PhD, Associate Professor of the of Ophthalmology department</p><p>Volokolamskoye highway, 91, Moscow, 125371</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трубилин</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Trubilin</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трубилин Владимир Николаевич, доктор медицинских наук, профессор, заведующий кафедрой офтальмологии</p><p>Волоколамское шоссе, 91, Москва, 125371</p></bio><bio xml:lang="en"><p>Trubilin Vladimir N., МD, Professor, Head of the of Ophthalmology Department</p><p>Volokolamskoye highway, 91, Moscow, 125371</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8551-0661</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полунина</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Poluninа</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полунина Елизавета Геннадьевна, доктор медицинских наук, профессор, профессор кафедры офтальмологии</p><p>Волоколамское шоссе, 91, Москва, 125371</p></bio><bio xml:lang="en"><p>Poluninа Elizabet G., MD, Professor, professor of the of Ophthalmology Department</p><p>Volokolamskoye highway, 91, Moscow, 125371</p></bio><email xlink:type="simple">lpolunina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8594-2395</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каспарова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kasparova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Каспарова Евгения Аркадьевна, кандидат медицинских наук, ведущий научный сотрудник отдела патологии оптических сред глаза</p><p>ул. Россолимо, 11а, б, Москва, 119021</p></bio><bio xml:lang="en"><p>Kasparova Evgeniya A., PhD, leading research officer of the optical media of the Eye pathology department</p><p>Rossolimo str., 11A, B, Moscow, 119021</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Анджелова</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Andzhelova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анджелова Диана Владимировна, доктор медицинских наук, старший научный сотрудник</p><p>ул. Россолимо, 11а, б, Москва, 119021</p></bio><bio xml:lang="en"><p>Andzhelova Diana V., МD, senior research officer</p><p>Rossolimo str., 11A, B, Moscow, 119021</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мирзабекова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mirzabekova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мирзабекова Каринэ Арменовна, кандидат медицинских наук, врач-офтальмолог</p><p>ул. 3-я Тверская-Ямская, 56/6, Москва, 125047</p></bio><bio xml:lang="en"><p>Mirzabekova Karina A., PhD, ophthalmologist</p><p>3 Tverskaya-Yamskaya str., 56/6, Moscow, 125047</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евстигнеева</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Evstigneeva</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евстигнеева Юлия Владимировна, кандидат медицинских наук, офтальмолог</p><p>Рублевское шоссе, 48/1, Москва, 121609</p></bio><bio xml:lang="en"><p>Evstigneeva Yulia V., PhD, ophthalmologist</p><p>Rublevskoe highway, 48, Moscow, 121609</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чиненова</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chinenova</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чиненова Ксения Владимировна, кандидат медицинских наук, врач-офтальмолог</p><p>Рублевское шоссе, 48/1, Москва, 121609</p></bio><bio xml:lang="en"><p>Chinenova Ksenia V., PhD, ophthalmologist</p><p>Rublevskoe highway, 48, Moscow, 121609</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лещенко</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Leshenko</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лещенко Ирина Антоновна, кандидат медицинских наук, доцент кафедры офтальмологии</p><p>ул. Нижняя Первомайская, 70, Москва, 105203</p></bio><bio xml:lang="en"><p>Leshenko Irina A., PhD, Associate Professor of the of Ophthalmology department</p><p>Nizhnyaya Pervomaiskaya str., 70, Moscow, 105203</p></bio><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Академия постдипломного образования ФГБУ «Федеральный научно-клинический центр» Федерального медико-биологического агентства<country>Россия</country></aff><aff xml:lang="en">Academy of postgraduate education of FMBA of Russia<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБНУ «Научно-исследовательский институт глазных болезней имени М.М. Краснова»<country>Россия</country></aff><aff xml:lang="en">Krasnov Research Institute of Eye Diseases<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Офтальмологический центр Коновалова<country>Россия</country></aff><aff xml:lang="en">Konovalov Ophthalmology Center<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">Офтальмологическая клиника доктора Куренкова<country>Россия</country></aff><aff xml:lang="en">Ophthalmology Clinic of Dr. Kurenkov<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru">ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">National Medical and Surgical Center named after N.I. Pirogov<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>03</month><year>2025</year></pub-date><volume>22</volume><issue>1</issue><fpage>74</fpage><lpage>83</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Трубилин А.В., Трубилин В.Н., Полунина Е.Г., Каспарова Е.А., Анджелова Д.В., Мирзабекова К.А., Евстигнеева Ю.В., Чиненова К.В., Лещенко И.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Трубилин А.В., Трубилин В.Н., Полунина Е.Г., Каспарова Е.А., Анджелова Д.В., Мирзабекова К.А., Евстигнеева Ю.В., Чиненова К.В., Лещенко И.А.</copyright-holder><copyright-holder xml:lang="en">Trubilin А.V., Trubilin V.N., Poluninа E.G., Kasparova E.A., Andzhelova D.V., Mirzabekova K.A., Evstigneeva Y.V., Chinenova K.V., Leshenko I.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/2581">https://www.ophthalmojournal.com/opht/article/view/2581</self-uri><abstract><p>В первой части статьи была представлена разработанная клиническая классификация степени тяжести синдрома сухого глаза 2024, которая учитывает не только объективные показатели состояния слезопродукции и степени выраженности воспаления тканей глазной поверхности, но и субъективные показатели — жалобы пациентов (шкала качества жизни SPEED). Данная классификация позволяет определить степень выраженности синдрома сухого глаза (ССГ), что, в свою очередь, дает возможность выбора адекватного объема и вида терапии этого заболевания. Представленное в данной статье исследование, проведенное на базе анкетирования экспертов-офтальмологов (метод Дельфи), позволило сформулировать алгоритм лечения синдрома сухого глаза при применении разработанной комплексной клинической классификации степени тяжести данной патологии. Эксперт-офтальмолог определял показания для назначения различных групп медикаментозных препаратов: слезозаменители, корнеопротекторы: гели с содержанием декспантенола, мазевые формы. Противовоспалительная терапия: дексаметазон, противоаллергические, нестероидные противовоспалительные препараты, препараты крови (аутологичная/алогенная сыворотка, PRP), циклоспорин, антисептики. Физиотерапевтическое лечение — гигиена век: теплые компрессы / орошение поверхности век теплой водой + самомассаж век, IPL-терапия, система Aktiva, система Plasma jett. Алгоритм позволяет определить показания для 13 видов терапии синдрома сухого глаза, рекомендованных к применению международной рабочей группой The Tear Film &amp; Ocular Surface в зависимости от степени тяжести синдрома сухого глаза (слабая, средняя, тяжелая), наличия сопутствующей патологии или приема лекарственных средств на постоянной основе, а также длительности ССГ. Учитывая высокий уровень согласованности экспертов в оценке (коэффициент каппа Рэндольфа выше 0,6) при составлении алгоритма, его можно рекомендовать к применению в широкой офтальмологической практике, включая первичное амбулаторно-поликлиническое звено.</p></abstract><trans-abstract xml:lang="en"><p>The first part of the article presented the developed clinical classification of the severity of dry eye syndrome 2024, which takes into account not only objective indicators of the state of tear production and the degree of inflammation of the tissues of the ocular surface, but also subjective indicators — patient complaints (SPEED quality of life scale). This classification allows to determine the severity of dry eye syndrome (DES), which in turn makes it possible to choose an adequate volume and type of therapy for this disease. The study presented in this article, conducted on the basis of a questionnaire of ophthalmologist experts (Delphi method), made it possible to formulate an algorithm for treating dry eye syndrome using the developed comprehensive clinical classification of the severity of this pathology. The ophthalmologist expert determined the indications for prescribing various groups of drugs — tear substitutes, corneoprotectors: gels containing dexpanthenol, ointment forms. Anti-inflammatory therapy — dexamethasone, antiallergic, nonsteroidal anti-inflammatory drugs, blood products (autologous/alogeneic serum, PRP), cyclosporine, antiseptics. Physiotherapeutic treatment — eyelid hygiene: warm compresses/irrigation of the eyelid surface with warm water + eyelid self-massage, IPL therapy, Aktiva system, Plasma jett system. The algorithm allows to determine indications for 13 types of dry eye syndrome therapy recommended for use by the international working group The Tear Film &amp; Ocular Surface depending on the severity of dry eye syndrome (mild, moderate, severe), the presence of concomitant pathology or taking medications on an ongoing basis, as well as the duration of dry eye syndrome. Given the high level of expert agreement in the assessment (Randolph kappa coefficient above 0.6) when compiling the algorithm, it can be recommended for use in a wide ophthalmological practice, including primary outpatient care.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>офтальмология</kwd><kwd>синдром сухого глаза</kwd><kwd>глазная поверхность</kwd><kwd>диагностика синдрома сухого глаза</kwd><kwd>классификация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ophthalmology</kwd><kwd>dry eye syndrome</kwd><kwd>ocular surface</kwd><kwd>dry eye syndrome diagnostics</kwd><kwd>classification</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин АВ, Трубилин ВН, Полунина ЕГ, Каспарова ЕА. Новая комплексная клиническая классификация степени тяжести синдрома сухого глаза 2024. Часть 1. Офтальмология. 2024;21(4):709–715.</mixed-citation><mixed-citation xml:lang="en">Трубилин АВ, Трубилин ВН, Полунина ЕГ, Каспарова ЕА. Новая комплексная клиническая классификация степени тяжести синдрома сухого глаза 2024. Часть 1. Офтальмология. 2024;21(4):709–715.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Troisi M, Del Prete S, Troisi S, Marasco D, Rinaldi M, Costagliola C. Scanning Electron Microscopy (SEM) Evaluation of the Ultrastructural Effects on Conjunctival Epithelial Cells of a New Multiple-Action Artificial Tear Containing Cross-Linked Hyaluronic Acid, Cationic Liposomes and Trehalose. Biomedicines. 2024 Aug 23;12(9):1945. doi: 10.3390/biomedicines12091945.</mixed-citation><mixed-citation xml:lang="en">Troisi M, Del Prete S, Troisi S, Marasco D, Rinaldi M, Costagliola C. Scanning Electron Microscopy (SEM) Evaluation of the Ultrastructural Effects on Conjunctival Epithelial Cells of a New Multiple-Action Artificial Tear Containing Cross-Linked Hyaluronic Acid, Cationic Liposomes and Trehalose. Biomedicines. 2024 Aug 23;12(9):1945. doi: 10.3390/biomedicines12091945.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Schrage NF, Frentz M, Reim M. Changing the composition of buffered eye-drops prevents undesired side effects. Br J Ophthalmol. 2010 Nov;94(11):1519–1522. doi: 10.1136/bjo.2009.177386.</mixed-citation><mixed-citation xml:lang="en">Schrage NF, Frentz M, Reim M. Changing the composition of buffered eye-drops prevents undesired side effects. Br J Ophthalmol. 2010 Nov;94(11):1519–1522. doi: 10.1136/bjo.2009.177386.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, Labetoulle M, Malachkova N, Meloni M, Utheim TP, Rolando M. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642–8652. doi: 10.26355/eurrev_202009_22801.</mixed-citation><mixed-citation xml:lang="en">Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, Labetoulle M, Malachkova N, Meloni M, Utheim TP, Rolando M. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8642–8652. doi: 10.26355/eurrev_202009_22801.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rajendraprasad RM, Kwatra G, Batra N. Carboxymethyl Cellulose versus Hydroxypropyl Methylcellulose Tear Substitutes for Dry Eye Due to Computer Vision Syndrome: Comparison of Efficacy and Safety. Int J Appl Basic Med Res. 2021 Jan-Mar;11(1):4–8. doi: 10.4103/ijabmr.IJABMR_399_20.</mixed-citation><mixed-citation xml:lang="en">Rajendraprasad RM, Kwatra G, Batra N. Carboxymethyl Cellulose versus Hydroxypropyl Methylcellulose Tear Substitutes for Dry Eye Due to Computer Vision Syndrome: Comparison of Efficacy and Safety. Int J Appl Basic Med Res. 2021 Jan-Mar;11(1):4–8. doi: 10.4103/ijabmr.IJABMR_399_20.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Huang R, Su C, Fang L, Lu J, Chen J, Ding Y. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022 Oct;42(10):3253–3272. doi: 10.1007/s10792-022-02320-7.</mixed-citation><mixed-citation xml:lang="en">Huang R, Su C, Fang L, Lu J, Chen J, Ding Y. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022 Oct;42(10):3253–3272. doi: 10.1007/s10792-022-02320-7.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ahn H, Kim BY, Kim J, Ji YW, Jun I, Kim TI, Lee HK, Seo KY. How Long to Continue Eyelid Hygiene to Treat Meibomian Gland Dysfunction. J Clin Med. 2022 Jan 20;11(3):529. doi: 10.3390/jcm11030529.</mixed-citation><mixed-citation xml:lang="en">Ahn H, Kim BY, Kim J, Ji YW, Jun I, Kim TI, Lee HK, Seo KY. How Long to Continue Eyelid Hygiene to Treat Meibomian Gland Dysfunction. J Clin Med. 2022 Jan 20;11(3):529. doi: 10.3390/jcm11030529.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tanabe H, Kaido M, Kawashima M, Ishida R, Ayaki M, Tsubota K. Effect of Eyelid Hygiene Detergent on Obstructive Meibomian Gland Dysfunction. J Oleo Sci. 2019 Jan 1;68(1):67–78. doi: 10.5650/jos.ess18161.</mixed-citation><mixed-citation xml:lang="en">Tanabe H, Kaido M, Kawashima M, Ishida R, Ayaki M, Tsubota K. Effect of Eyelid Hygiene Detergent on Obstructive Meibomian Gland Dysfunction. J Oleo Sci. 2019 Jan 1;68(1):67–78. doi: 10.5650/jos.ess18161.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bitton E, Ngo W, Dupont P. Eyelid hygiene products: A scoping review. Cont Lens Anterior Eye. 2019 Dec;42(6):591–597. doi: 10.1016/j.clae.2019.09.008.</mixed-citation><mixed-citation xml:lang="en">Bitton E, Ngo W, Dupont P. Eyelid hygiene products: A scoping review. Cont Lens Anterior Eye. 2019 Dec;42(6):591–597. doi: 10.1016/j.clae.2019.09.008.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Медведев ИБ, Трубилин ВН, Полунина ЕГ, Дергачева НН, Анджелова ДВ, Евстигнеева ЮВ. Современные возможности физиотерапевтического лечения дисфункции мейбомиевых желез. Офтальмология. 2022;19(2):235–241.</mixed-citation><mixed-citation xml:lang="en">Медведев ИБ, Трубилин ВН, Полунина ЕГ, Дергачева НН, Анджелова ДВ, Евстигнеева ЮВ. Современные возможности физиотерапевтического лечения дисфункции мейбомиевых желез. Офтальмология. 2022;19(2):235–241.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин АВ, Полунина ЕГ, Трубилин ВН, Закатянский ВС. Профилактика синдрома сухого глаза перед проведением факоэмульсификации катаракты у пациентов с косметологическими процедурами в периорбитальной зоне в анамнезе. Офтальмология. 2024;21(3):517–526.</mixed-citation><mixed-citation xml:lang="en">Трубилин АВ, Полунина ЕГ, Трубилин ВН, Закатянский ВС. Профилактика синдрома сухого глаза перед проведением факоэмульсификации катаракты у пациентов с косметологическими процедурами в периорбитальной зоне в анамнезе. Офтальмология. 2024;21(3):517–526.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gade A, Vasile GF, Hohman MH, Rubenstein R. Intense Pulsed Light (IPL) Therapy. 2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 35593833.</mixed-citation><mixed-citation xml:lang="en">Gade A, Vasile GF, Hohman MH, Rubenstein R. Intense Pulsed Light (IPL) Therapy. 2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 35593833.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Майчук ДЮ, Лошкарева АО, Цветкова ТВ. Алгоритм комплексной терапии синдрома сухого глаза с дисфункцией мейбомиевых желез интенсивным импульсным светом (IPL) в сочетании с гигиеной век и слезозамещением. Офтальмология. 2020;17(3s):640–647.</mixed-citation><mixed-citation xml:lang="en">Майчук ДЮ, Лошкарева АО, Цветкова ТВ. Алгоритм комплексной терапии синдрома сухого глаза с дисфункцией мейбомиевых желез интенсивным импульсным светом (IPL) в сочетании с гигиеной век и слезозамещением. Офтальмология. 2020;17(3s):640–647.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Li S, Yang K, Wang J, Li S, Zhu L, Feng J, Tian L, Jie Y. Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients. Ophthalmol Ther. 2022 Feb;11(1):261–270. doi: 10.1007/s40123021‑00431‑5.</mixed-citation><mixed-citation xml:lang="en">Li S, Yang K, Wang J, Li S, Zhu L, Feng J, Tian L, Jie Y. Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients. Ophthalmol Ther. 2022 Feb;11(1):261–270. doi: 10.1007/s40123021‑00431‑5.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Shin KY, Lim DH, Moon CH, Kim BJ, Chung TY. Intense pulsed light plus meibomian gland expression versus intense pulsed light alone for meibomian glanddysfunction: A randomized crossover study. PLoS One. 2021 Mar 4;16(3):e0246245. doi: 10.1371/journal.pone.0246245.</mixed-citation><mixed-citation xml:lang="en">Shin KY, Lim DH, Moon CH, Kim BJ, Chung TY. Intense pulsed light plus meibomian gland expression versus intense pulsed light alone for meibomian glanddysfunction: A randomized crossover study. PLoS One. 2021 Mar 4;16(3):e0246245. doi: 10.1371/journal.pone.0246245.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cote S, Zhang AC, Ahmadzai V, Maleken A, Li C, Oppedisano J, Nair K, Busija L, Downie LE. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559. doi: 10.1002/14651858.CD013559.</mixed-citation><mixed-citation xml:lang="en">Cote S, Zhang AC, Ahmadzai V, Maleken A, Li C, Oppedisano J, Nair K, Busija L, Downie LE. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559. doi: 10.1002/14651858.CD013559.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vigo L, Pellegrini M, Carones F, Scorcia V, Giannaccare G. Short-Term Effects of a Novel Eye Mask Producing Heat and Vibration for the Treatment of Meibomian Gland Dysfunction: A Pilot Study. J Ophthalmol. 2021 Aug 17;2021:1370002. doi: 10.1155/2021/1370002.</mixed-citation><mixed-citation xml:lang="en">Vigo L, Pellegrini M, Carones F, Scorcia V, Giannaccare G. Short-Term Effects of a Novel Eye Mask Producing Heat and Vibration for the Treatment of Meibomian Gland Dysfunction: A Pilot Study. J Ophthalmol. 2021 Aug 17;2021:1370002. doi: 10.1155/2021/1370002.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Vigo L, Pellegrini M, Carones F, Scorcia V, Giannaccare G. Outcomes of serial sessions of Activa mask combined with intense pulsed light therapy in patients with Meibomian gland dysfunction. BMC Ophthalmol. 2022 Jul 19;22(1):313. doi: 10.1186/s12886-022-02538-0.</mixed-citation><mixed-citation xml:lang="en">Vigo L, Pellegrini M, Carones F, Scorcia V, Giannaccare G. Outcomes of serial sessions of Activa mask combined with intense pulsed light therapy in patients with Meibomian gland dysfunction. BMC Ophthalmol. 2022 Jul 19;22(1):313. doi: 10.1186/s12886-022-02538-0.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fait T, Baltazár T, Bubenickova L, Kestranek J, Stepan M, Muller M, Turcan P. Treatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Study. J Clin Med. 2023 Sep 27;12(19):6234. doi: 10.3390/jcm12196234.</mixed-citation><mixed-citation xml:lang="en">Fait T, Baltazár T, Bubenickova L, Kestranek J, Stepan M, Muller M, Turcan P. Treatment of Vulvovaginal Laxity by Electroporation: The Jett Plasma Medical for Her II Study. J Clin Med. 2023 Sep 27;12(19):6234. doi: 10.3390/jcm12196234.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zemanova M. Treatment of mild forms of blepharitis using direct plasma discharge Advances in Ophthalmology &amp; Visual System Preliminary Report. Advances in Ophthalmology &amp; Visual System. 2020; 10:127–130. doi: 10.15406/aovs.2020.10.00397.</mixed-citation><mixed-citation xml:lang="en">Zemanova M. Treatment of mild forms of blepharitis using direct plasma discharge Advances in Ophthalmology &amp; Visual System Preliminary Report. Advances in Ophthalmology &amp; Visual System. 2020; 10:127–130. doi: 10.15406/aovs.2020.10.00397.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kumari S, Dandamudi M, Rani S, Behaeghel E, Behl G, Kent D, O’Reilly NJ, O’Donovan O, McLoughlin P, Fitzhenry L. Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease. Pharmaceutics. 2021 Jun 18;13(6):905. doi: 10.3390/pharmaceutics13060905.</mixed-citation><mixed-citation xml:lang="en">Kumari S, Dandamudi M, Rani S, Behaeghel E, Behl G, Kent D, O’Reilly NJ, O’Donovan O, McLoughlin P, Fitzhenry L. Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease. Pharmaceutics. 2021 Jun 18;13(6):905. doi: 10.3390/pharmaceutics13060905.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lin MX, Guo L, Saldanha IJ, VanCourt S, Zeng J, Karakus S, Hessen M, Li G, Akpek EK. Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye: A Randomized Controlled Trial. Ophthalmology. 2024 Sep;131(9):1033–1044. doi: 10.1016/j.ophtha.2024.03.010.</mixed-citation><mixed-citation xml:lang="en">Lin MX, Guo L, Saldanha IJ, VanCourt S, Zeng J, Karakus S, Hessen M, Li G, Akpek EK. Dexamethasone Intracanalicular Insert for Clinically Significant Aqueous-Deficient Dry Eye: A Randomized Controlled Trial. Ophthalmology. 2024 Sep;131(9):1033–1044. doi: 10.1016/j.ophtha.2024.03.010.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Jin X, Wang J, Li X, Zhang H. Dexamethasone attenuates dry eye-induced pyroptosis by regulating the KCNQ1OT1/miR-214 cascade. Steroids. 2022 Oct;186:109073. doi: 10.1016/j.steroids.2022.109073.</mixed-citation><mixed-citation xml:lang="en">Li X, Jin X, Wang J, Li X, Zhang H. Dexamethasone attenuates dry eye-induced pyroptosis by regulating the KCNQ1OT1/miR-214 cascade. Steroids. 2022 Oct;186:109073. doi: 10.1016/j.steroids.2022.109073.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Utheim TP, Chen X, Fineide F, Steinkjer T, Heegaard S, Kolko M, Dartt DA, Khan AZ. Response predictors of a topical corticosteroid-based regimen for dry eyes: A real-life study. Acta Ophthalmol. 2025 Feb;103(1):93–98. doi: 10.1111/aos.16758.</mixed-citation><mixed-citation xml:lang="en">Utheim TP, Chen X, Fineide F, Steinkjer T, Heegaard S, Kolko M, Dartt DA, Khan AZ. Response predictors of a topical corticosteroid-based regimen for dry eyes: A real-life study. Acta Ophthalmol. 2025 Feb;103(1):93–98. doi: 10.1111/aos.16758.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen A, Kolluru A, Beglarian T. Dry eye disease: A review of anti-inflammatory therapies. Taiwan J Ophthalmol. 2023 Feb 13;13(1):3–12. doi: 10.4103/2211-5056.369606.</mixed-citation><mixed-citation xml:lang="en">Nguyen A, Kolluru A, Beglarian T. Dry eye disease: A review of anti-inflammatory therapies. Taiwan J Ophthalmol. 2023 Feb 13;13(1):3–12. doi: 10.4103/2211-5056.369606.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Messmer EM. Pathophysiology of dry eye disease and novel therapeutic targets. Exp Eye Res. 2022 Apr;217:108944. doi: 10.1016/j.exer.2022.108944.</mixed-citation><mixed-citation xml:lang="en">Messmer EM. Pathophysiology of dry eye disease and novel therapeutic targets. Exp Eye Res. 2022 Apr;217:108944. doi: 10.1016/j.exer.2022.108944.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Vazirani J, Sridhar U, Gokhale N, Doddigarla VR, Sharma S, Basu S. Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines. Indian J Ophthalmol. 2023 Apr;71(4):1357–1363. doi: 10.4103/IJO.IJO_2756_22. PMID: 37026267; PMCID: PMC10276663.</mixed-citation><mixed-citation xml:lang="en">Vazirani J, Sridhar U, Gokhale N, Doddigarla VR, Sharma S, Basu S. Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines. Indian J Ophthalmol. 2023 Apr;71(4):1357–1363. doi: 10.4103/IJO.IJO_2756_22. PMID: 37026267; PMCID: PMC10276663.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Каспарова ЕA, Криволапова ДА. Сыворотка крови в лечении эпителиопатии различного генеза. Клинические наблюдения. Офтальмология. 2024;21(4):769–776.</mixed-citation><mixed-citation xml:lang="en">Kasparova EA, Krivolapova DA. Blood Serum in the Treatment of Epitheliopathy of Various Genesis. Clinical Observations. Ophthalmology in Russia. 2024;21(4):769–776 (In Russ.). doi: 10.18008/1816-5095-2024-4-769-776.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Sharkawy HE, Kantarci A, Deady J. Platelet — rich plasma: growth factors and proand anti -inflammatory properties. J. Periodontol. 2007;78(4):661–669. doi: 10.5272/jimab.2016224.1379.</mixed-citation><mixed-citation xml:lang="en">Sharkawy HE, Kantarci A, Deady J. Platelet — rich plasma: growth factors and proand anti -inflammatory properties. J. Periodontol. 2007;78(4):661–669. doi: 10.5272/jimab.2016224.1379.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kang MJ, Lee JH, Hwang J, Chung SH. Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sjögren’s syndrome: a randomized trial. Sci Rep. 2023 Nov 7;13(1):19279. doi: 10.1038/s41598-023-46671-2.</mixed-citation><mixed-citation xml:lang="en">Kang MJ, Lee JH, Hwang J, Chung SH. Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sjögren’s syndrome: a randomized trial. Sci Rep. 2023 Nov 7;13(1):19279. doi: 10.1038/s41598-023-46671-2.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Jongkhajornpong P, Lekhanont K, Rattanasiri S, Numthavaj P, McKay G, Attia J, Thakkinstian A. Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial. BMJ Open Ophthalmol. 2024 Oct 8;9(1):e001857. doi: 10.1136/bmjophth-2024-001857.</mixed-citation><mixed-citation xml:lang="en">Jongkhajornpong P, Lekhanont K, Rattanasiri S, Numthavaj P, McKay G, Attia J, Thakkinstian A. Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial. BMJ Open Ophthalmol. 2024 Oct 8;9(1):e001857. doi: 10.1136/bmjophth-2024-001857.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Jongkhajornpong P, Lekhanont K, Rattanasiri S, Numthavaj P, McKay G, Attia J, Thakkinstian A. Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial. BMJ Open Ophthalmol. 2024 Oct 8;9(1):e001857. doi: 10.1136/bmjophth-2024-001857.</mixed-citation><mixed-citation xml:lang="en">Jongkhajornpong P, Lekhanont K, Rattanasiri S, Numthavaj P, McKay G, Attia J, Thakkinstian A. Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial. BMJ Open Ophthalmol. 2024 Oct 8;9(1):e001857. doi: 10.1136/bmjophth-2024-001857.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Balal S, Udoh A, Pappas Y, Cook E, Barton G, Hassan A, Hayden K, Bourne RRA, Ahmad S, Pardhan S, Harrison M, Sharma B, Wasil M, Sharma A. The feasibility of finger prick autologous blood (FAB) as a novel treatment for severe dry eye disease (DED): protocol for a randomised controlled trial. BMJ Open. 2018 Oct 31;8(10):e026770. doi: 10.1136/bmjopen-2018-026770.</mixed-citation><mixed-citation xml:lang="en">Balal S, Udoh A, Pappas Y, Cook E, Barton G, Hassan A, Hayden K, Bourne RRA, Ahmad S, Pardhan S, Harrison M, Sharma B, Wasil M, Sharma A. The feasibility of finger prick autologous blood (FAB) as a novel treatment for severe dry eye disease (DED): protocol for a randomised controlled trial. BMJ Open. 2018 Oct 31;8(10):e026770. doi: 10.1136/bmjopen-2018-026770.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gao M, Zhao L, Liang R, Zhu Q, Zhao Q, Kong X. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren’s Syndrome. Ocul Immunol Inflamm. 2023 Oct;31(8):1662–1668. doi: 10.1080/09273948.2022.2094812.</mixed-citation><mixed-citation xml:lang="en">Gao M, Zhao L, Liang R, Zhu Q, Zhao Q, Kong X. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren’s Syndrome. Ocul Immunol Inflamm. 2023 Oct;31(8):1662–1668. doi: 10.1080/09273948.2022.2094812.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Moawad P, Shamma R, Hassanein D, Ragab G, El Zawahry O. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome. Eur J Ophthalmol. 2022 Jan;32(1):673–679. doi: 10.1177/1120672121992680.</mixed-citation><mixed-citation xml:lang="en">Moawad P, Shamma R, Hassanein D, Ragab G, El Zawahry O. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome. Eur J Ophthalmol. 2022 Jan;32(1):673–679. doi: 10.1177/1120672121992680.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, Hoshino-Ruiz DR, Albers MB, Santo RM, Hida RY. Treatment of Sjögren’s syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study. Cont Lens Anterior Eye. 2015 Oct;38(5):373–378. doi: 10.1016/j.clae.2015.04.004.</mixed-citation><mixed-citation xml:lang="en">Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, Hoshino-Ruiz DR, Albers MB, Santo RM, Hida RY. Treatment of Sjögren’s syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study. Cont Lens Anterior Eye. 2015 Oct;38(5):373–378. doi: 10.1016/j.clae.2015.04.004.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Nye M, Rudner S, Bielory L. Emerging therapies in allergic conjunctivitis and dry eye syndrome. Expert Opin Pharmacother. 2013 Aug;14(11):1449–1465. doi: 10.1517/14656566.2013.802773.</mixed-citation><mixed-citation xml:lang="en">Nye M, Rudner S, Bielory L. Emerging therapies in allergic conjunctivitis and dry eye syndrome. Expert Opin Pharmacother. 2013 Aug;14(11):1449–1465. doi: 10.1517/14656566.2013.802773.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Трубилин ВН, Полунина ЕГ, Кожухов АА, Куренков ВВ, Морева НВ, Трубилин АВ. Медикаментозная терапия конъюнктивитов. Литературный обзор. The EYE ГЛАЗ. 2023;25(3):225–233.</mixed-citation><mixed-citation xml:lang="en">Trubilin VN, Poluninа EG, Kozhukhov AA, Kurenkov VV, Moreva NV, Trubilin AV. Medical therapy for conjunctivitis. Literature review. The EYE GLAZ. 2023;25(3):225–233 (In Russ.). doi: 10.33791/2222-4408-2023-3-225-233.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Craig JP, Alves M, Wolffsohn JS, Downie LE, Efron N, Galor A, Gomes JAP, Jones L, Markoulli M, Stapleton F, Starr CE, Sullivan AG, Willcox MDP, Sullivan DA. TFOS Lifestyle Report Introduction: A Lifestyle Epidemic — Ocular Surface Disease. Ocul Surf. 2023 Apr;28:304–309. doi: 10.1016/j.jtos.2023.04.014. Epub 2023 Apr 29. PMID: 37121544.</mixed-citation><mixed-citation xml:lang="en">Craig JP, Alves M, Wolffsohn JS, Downie LE, Efron N, Galor A, Gomes JAP, Jones L, Markoulli M, Stapleton F, Starr CE, Sullivan AG, Willcox MDP, Sullivan DA. TFOS Lifestyle Report Introduction: A Lifestyle Epidemic — Ocular Surface Disease. Ocul Surf. 2023 Apr;28:304–309. doi: 10.1016/j.jtos.2023.04.014. Epub 2023 Apr 29. PMID: 37121544.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
